HITLAB, the independent healthcare innovation and research laboratory affiliated with Columbia University, released its Summary of Evidence Paper on MedsEngine. HITLAB was engaged to conduct an independent, structured evaluation of the MedsEngine platform and its supporting clinical evidence base. The evaluation, completed in March 2026, encompassed a full walkthrough of all four disease modules, clinical workflow integration assessment, usability analysis using the Nielsen heuristic framework, a comprehensive review of the peer-reviewed evidence, and economic value analysis.

HITLAB Chairman, Stan Kachnowski, stated, “MedsEngine is among the most clinically rigorous and outcomes-validated decision support platforms HITLAB has evaluated. In a landscape crowded with digital health promises, MedsEngine delivers something rare: a decade of real-world evidence that durably moves the needle on chronic disease control at scale.”

The four disease modules that MedsEngine supports impact over 60 per cent of the adult population and represent nearly 64 per cent of chronic disease costs. Dr Doug Romer, MedsEngine CMO, stated, “HITLAB’s findings identify the improved outcomes and cost benefits derived from using MedsEngine to treat chronic diseases. Users achieved US-leading hypertension control for over 90 per cent of patients in less than 2 office visits. Clinicians can provide guideline-directed treatment for type 2 diabetes and cholesterol management in a matter of seconds.”

MedsEngine uses secure FHIR-based interoperability with EHRs to turn patient-specific data already available in the EHR into guideline-directed recommendations within the clinician’s workflow, reducing manual review and improving office efficiency.